Business
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 $28 million in cash, cash equivalents, restricted cash and capital commitments expected to fund current operating plan through the first half of 2027 ALAMEDA, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra
About this update from Vivani Medical, Inc.
[{"type":"image","alt":"Vivani Medical, Inc.","displaySize":"","headline":null,"caption":"Vivani Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/c23870f4ae46a8fd33cfe7a0a48ef637"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aU1HV9H8XgPgL8OdypT.mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c23870f4ae46a8fd33cfe7a0a48ef637","width":300,"height":300},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/aU1HV9H8XgPgL8OdypT.mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c23870f4ae46a8fd33cfe7a0a48ef637","width":300,"height":300}},"lazy":false},{"type":"text","content":"Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026","length":163,"tagName":"p"},{"type":"text","content":"$28 million in cash, cash equivalents, restricted cash and capital commitments expected to fund current operating plan through the first half of 2027","length":149,"tagName":"p"},{"type":"text","content":"ALAMEDA, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants utilizing its proprietary NanoPortal™ technology, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.","length":380,"tagName":"p"},{"type":"text","content":"Vivani Chief Executive Officer Adam Mendelsohn, Ph.D., stated, “I’m very pleased with the progress our team made in the first quarter. We are on track to initiate the first study in our SLIM™ Clinical Program (Semaglutide ultra Long-acting IMplant in obesity). Our Phase 1 study of NPM-139, also known as SLIM-1, will be conducted in Australia and is anticipated to start mid-year 2026. Based on our prior experience with the execution of our first-in-human LIBERATE-1 clinical trial in 2025, we anticipate top-line SLIM-1 results by the end of this year. In parallel, we continue to make good progress on our next generation NPM-139 implant configuration, which is designed to accommodate larger doses of semaglutide in-line with Wegovy® dosing...